MORPHO-FUNCTIONAL CHARACTERISTICS OF THE SCIATIC NERVE IN THE LATE TERMS OF EXPERIMENTAL PACLITAXEL-INDUCED PERIPHERAL NEUROPATHY UNDER THE CORRECTION OF 2-ETHYL-6-METHYL-3-HYDROXYPYRIDINE SUCCINATE

Authors:

Abstract:

6 out of 10 patients undergoing treatment for breast cancer, ovarian cancer, and non-small cell lung cancer suffer from the neurotoxicity of the chemotherapy drug Paclitaxel, namely paclitaxel-induced peripheral neuropathy. Among them, one in four needs to reduce the dose, postpone the treatment or even stop the therapy. Previous attempts to use various neuroprotective agents in humans and animal models have not shown sufficient effectiveness in preventing or significantly reducing the intensity of paclitaxel-induced peripheral neuropathy manifestations. The purpose of our study was to establish the effect of the neuroprotective agent 2-ethyl-6-methyl-3-hydroxypyridine succinate on the morpho-functional parameters of the sciatic nerve in experimental paclitaxel-induced peripheral neuropathy. In the experiment, 56 white rats weighing 150–200 g were used. Paclitaxel was administered intraperitoneally to the animals at a dose of 2 mg/kg body weight 4 times after one day, after which the animals were divided into an experimental group – 24 animals that were administered 2-ethyl-6-methyl-3-hydroxypyridine succinate and a control group (24 animals, introduction of water for injections) groups. The results of the “hot plate” tests and von Frey monofilaments showed that the use of 2-ethyl-6-methyl-3-hydroxypyridine succinate reliably reduces the manifestations of peripheral neuropathy caused by paclitaxel on the 28th and 60th days of the experiment. In rats treated with HS, destructive-dystrophic phenomena in the myelin nerve fibers of the sciatic nerve are less pronounced on the 60th, 90th, and 120th days of the experiment. The results of the electron microscopic study are fully consistent with the data of neurophysiological studies and indicate the possibility of using 2-ethyl-6-methyl-3-hydroxypyridine succinate as an effective neuroprotector in paclitaxel-induced peripheral neuropathy.

Keywords:

paclitaxel chemotherapy neuropathy nerve peripheral nervous system

References:

1. Dmytriev DV. Vykorystannya analheziyi poperechnoho ploskostnoho bloku (blokada ploshchyny krana – trabsusu zhyvota) zmenshuye riven toll-podibnykh retseptoriv (TLR4) u plazmi markera hiperalheziyi v rannomu pislyaoperatsiynomu periodi.. Emergency medicine. 2015;8(71):50–54. [in Ukrainian].
2. Dovga NZ. Ultrastrukturni zminy v sitkivtsi oka pry korektsiyi paklitaksel-indukovanoyi retynotoksychnosti antyoksydantnym preparatom. Ukrainian journal of medicine, biology and sport. 2017. No. 5. P. 20–25. [in Ukrainian].
3. Bannon AW. Models of pain: hot-plate and formalin test in rodents. Curr Protoc Pharmacol. 2001 May;Chapter 5:Unit 5.7. doi: 10.1002/0471141755.ph0507s00. PMID: 21971809.
4. Cavaletti G, Marmiroli P. Chemotherapy-induced peripheral neurotoxicity. Curr. Opin. Neurol. 2015;28:500–507. doi: 10.1097/WCO.00000000000002344.
5. Gewandter JS, Mohile SG, Heckler CE, Ryan JL, Kirshner JJ, Flynn PJ et al. A phase III randomized, placebo-controlled study of topical amitriptyline and ketamine for chemotherapy-induced peripheral neuropathy (CIPN): a University of Rochester CCOP study of 462 cancer survivors. Supportive Care in Cancer. 2014;22:1807–14.
6. Gornstein EL, Schwarz TL. Neurotoxic mechanisms of paclitaxel are local to the distal axon and independent of transport defects. Exp Neurol. 2017 Feb;288:153–66.
7. Herashchenko S, Ostrovskyi M, Kulynych H, Markiv I. Neuroprotective effect of 2-ethyl-6-methyl-3-hydroxypyridine succinate on the sciatic nerve and its segmental centers in experimental paclitaxel-induced peripheral neuropathy. Reports of Morphology. Vol.29. N4. 2023. P.70–78. doi: 10.31393/morphology-journal-2023-29(4)-10.
8. Huang H, He M, Liu L, Huang L. Vitamin E does not decrease the incidence of chemotherapy-induced peripheral neuropathy: a meta-analysis. Contemporary Oncology. 2016;20(3):237–41.
9. Magdy T, Burmeister BT, Burridge PW. Validating the pharmacogenomics of chemotherapy-induced cardiotoxicity: What is missing? Pharmacol Ther. 2016Dec;168:113–25.
10. Nehate C, Jain S, Saneja A, Khare V, Alam N, Dubey RD et al. Paclitaxel formulations: challenges and novel delivery options. Curr Drug Deliv. 2014; 11(6):666–86.
11. Polomano RC, Mannes AJ, Clark US, Bennett GJ. A painful peripheral neuropathy in the rat produced by the chemotherapeutic drug, paclitaxel. Pain. 2001 Dec;94(3):293–304. doi: 10.1016/S0304-3959(01)00363-3. PMID: 11731066.
12. Schloss JM, Colosimo M, Airey C, Masci P, Linnane AW, Vitetta L. A randomised, placebo-controlled trial assessing the efficacy of an oral B group vitamin in preventing the development of chemotherapy-induced peripheral neuropathy (CIPN). Support Care Cancer. 2017 Jan;25(1):195–204.
13. Seretny M, Currie GL, Sena ES, Ramnarine S, Grant R, Macleod MR et al. Incidence, prevalence, and predictors of chemotherapy-induced peripheral neuropathy: A systematic review and meta-analysis. Pain. 2014;155:2461–70. doi: 10.1016/j.pain.2014.09.020
14. Tufano AM, Teplinsky E, Landry CA. Updates in Neoadjuvant Therapy for Triple Negative Breast Cancer. Clin Breast Cancer. 2021 Feb;21(1):1–9. doi: 10.1016/j.clbc.2020.07.001. Epub 2020 Jul 3. PMID: 32800492.

Publication:

«World of Medicine and Biology» Vol. 20 No. 87 (2024) , с. 214-220
УДК 616-009+616-009.6+611.08

DOI:

https://doi.org/10.26724/2079-8334-2024-1-87-214-220